• Pharma industry M&A deals in June 2019 total $101.32bn globally

  Total pharma industry M&A deals in June 2019 worth $101.32bn were announced globally, according to GlobalData’s deals database. Embed this…
  Read More…

• Boehringer acquires AMAL Therapeutics for $366m

  Boehringer Ingelheim has expanded its cancer immunology portfolio with the acquisition of Swiss biotechnology firm...
  Read More...

• Recursion secures funds to support AI-based drug discovery

  Artificial intelligence (AI) drug discovery firm Recursion Pharmaceuticals, has secured $121m in a series C...
  Read More...

• Pharma industry venture financing deals in June 2019 total $1.09bn globally

  Total pharma industry venture financing deals in June 2019 worth $1.09bn were announced globally, according to GlobalData’s deals database.  …
  Read More…

• AbbVie acquires STING pathway-focused Mavupharma

  Chicago-based AbbVie has announced its acquisition of Seattle-based oncology drug discovery company Mavupharma. The financial...
  Read More...

• Europe’s pharma industry sees a rise of 18.5% in deal activity in June 2019

  Europe’s pharma industry saw a rise of 18.5% in deal activity during June 2019, when compared with the last 12-month…
  Read More…

• Gilead and Galapagos deal: building on filgotinib agreement

  US-based Gilead has entered into a ten-year global research and development (R&D) collaboration agreement with...
  Read More...

• Gilead and Galapagos deepen R&D alliance with ten-year deal

  Gilead Sciences has expanded its partnership with Belgian biotech company Galapagos with a ten-year global...
  Read More...

• Recordati acquires rights to Signifor and osilodrostat from Novartis

  Recordati has agreed to acquire the global rights to two of Novartis’ medicines, Signifor and...
  Read More...

• Amgen and Novartis discontinue Alzheimer’s drug development programme

  Amgen and Novartis have announced the discontinuation of their clinical development programme for CNP520 (umibecestat),...
  Read More...